Kurz zu Chiron - 500 Beiträge pro Seite

[IWA Japan]

Produktpipeline
http://www.chiron.com/research/pipeline/static.html
aktuelle MArktprodukte
http://www.chiron.com/products/onMarket/static.html

Weitere INformationen erwünscht!

[Donnie Brasco]

zu CHIRON:


BUSINESSWEEK INVESTOR -- INSIDE WALL STREET

Why Chiron May Be on the Mend


Chiron (CHIR), like most other biotechs, has yet to recover from its big fall in March. The stock plunged from 67, hitting 34 in May--and is currently at 44. But ``recovery should accelerate from now on,`` predicts James McCamant, editor of Medical Technology Stock Letter in Berkeley, Calif.

The big drop was triggered in part by a revocation in Europe of a patent that had been given to another U.S. biotech company, Protein Design Labs. Chiron, which develops products to treat AIDS, cancer, cardiovascular disease, and hepatitis, owns many similar patents.

Oddly enough, McCamant expects a boost from a patent lawsuit that Chiron won in Germany. A Dusseldorf court has ruled that F. Hoffmann-LaRoche`s HIV diagnostic tests infringe Chiron`s patent. So Chiron is entitled to damages for Roche sales from 1993 and could stop Roche from selling the products.

McCamant has learned that Roche will soon settle and accept a Chiron license to continue selling its diagnostic products. McCamant expects Hoffmann will pay $100 million plus a fat royalty fee on sales of the licensed products.

Another fillip: On Jan. 5, 2001, Swiss drugmaker Novartis, which already owns 45% of Chiron, will be able to raise its stake. Some investors have been buying Chiron stock on the chance that Novartis may gobble up the rest.

By GENE G. MARCIAL


Dieser ericht erscheint am 26.Juni in der Businessweek, inside wall street. Klingt eigentlich ganz gut ...

MfG

[IWA Japan]

Chriron erhält 24 Millionen zur Entwicklung von AIDS-Impfstoff

Das Pharmaunternehmen Chiron Corp. (Nasdaq: CHIR) gab heute bekannt,
dass man vom National Institute of Health (NIH) für
einen 5-Jahres-Vertrag auserwählt wurde, um das HIV Impfstoff Programm
in menschlichen klinischen Tests fortzuführen. Der Vertrag umfasst Zahlungen
in einem Wert von 24 Millionen US-Dollar.

Als "Auserwählte"
erwartet man von der Firma, dass innerhalb von 5
Jahren ein Impstoff gefunden wird, der möglicherweise einen Schutz
vor AIDS bietet. Das Biotechunternehmen wird neuartige DNA und
Alphavirus Impstoffkandidaten, die auf HIV-1 Subtypus B basieren, die
in den USA und Europa häufig vorkommen, entwickeln.

Als
Teil des Vertrages wird Chiron auch an einem Impfstoff
gegen den Subtypus C -Virus, dem häufigsten Virus in
Afrika, Indien und China, arbeiten. Die Impfstoffe, hergestellt aus
einer HIV-Hülle und Kernproteingenen, sollen die Produktion von Antikörper
und T-Zellen stimulieren, die Viren und virenbefallene Zellen attackieren.

[RCZ]

Chiron mit positiver Phase II Studie

Chiron (Nasdaq: CHIR; WKN 869640) gab am Wochenende erfolgversprechende Phase II Daten ihres HIV Medikamentes bekannt.
Das Medikament, ein rekombinantes human interleukin-2, zeigt in Verbindung mit einer standard antiviral Therapie eine signifikante Steigerung der CD4+ T-Zellen ohne gleichzeitig die Viruskonzentration im Blut der Patienten zu steigern.
Das Medikament befindet sich zur Zeit bereits am Anfang von Phase III Studien, deren Abschluss nicht vor 2006 geplant ist.

[IWA Japan]

[IWA Japan]

Chiron ups 2000 EPS est.
--9:28 am - By Tomi Kilgore
Chiron (CHIR: news, msgs) is rallying 3 5/8 to 48 3/8 in the pre-market, after blowing away earnings estimates for its second quarter. The company said late Wednesday that operating profits were 30 cents a share, compared to the 18 cents it earned in the year-earlier period. On average, analysts were expecting earnings of 21 cents, according to First Call. Revenue came in at $241 million, which was 27 percent more than last year. Also, the company revised its earnings outlook for fiscal 2000. The company now expects to earn 80 to 85 cents a share this year, up from an earlier forecast of 78 cents.

[IWA Japan]

seht ihr, auch mit größeren BT kann man Geld verdienen

[IWA Japan]

seht ihr, auch mit größeren BT kann man Geld verdienen

[Don Speculazio]

Wie geht denn das mit den farbigen blizelnden Smileys???

Danke/H.

[siek]

Biotech-Unternehmen Chiron (CHIR) übernimmt für 700 Millionen Dollar in Aktien (38,50 Dollar pro Aktie) PathoGenesis Entwickler von Medikamenten zur Behandlung von chronischen Infektionskrankheiten PathoGenesis. Der Deal soll noch im 3Q oder 4Q in diesem Jahr abgeschlossen werden.

Boerse-online Webersteam

siek

[IWA Japan]

@DS: ein Sauerländer hats mal erklärt


Thread: Learning with Iron -- (leassion 1)

[IWA Japan]

hier nochmal orignal von W:O


Chiron kauft PathoGenesis

Die Biotechnologiefirma Chiron (Nasdaq: CHIR) kauft den Konkurrenten PathoGenesis
(Nasdaq: PGNS) für 700 Mio. US-Dollar in Cash. Dadurch
wird das Produktprotfolio von Chiron um Medikamente zur Bekämpfung
von Infektionskrankheiten erweitert.



Chiron wird laut den Vertragsvereinbarungen 38,50 Dollar
für eine Aktie von PathoGenesis bezahlen. Am Freitag notierten
die Anteilsscheine von PathoGenesis noch bei 32,75, also weit
unter dem Angebot. Im Moment liegen die Aktien aber
schon bei 38 Dollar.



Der Kauf wird wahrscheinlich im dritten
oder vierten Quartal abgschlossen sein, die Boards of Directors
beider Unternehmen haben der Transaktion bereits zugestimmt.



"Wir glauben, dass
diese Transaktion für beide Seiten der Aktionäre von Vorteil
ist," sagte Sean Lance, Chairman und CEO von Chiron.
"Es wird ein integriertes Unternehmen entstehen, das als globaler
Innovator in der Behandlung und Prävention von Infektionskrankheiten hervortreten
wird."



Chiron wurde von Donaldson Lufkin Jenrette beraten, während Goldman
Sachs die Interessen von PathoGenesis vertrat. Bereits im Juni
teilte PathoGenesis mit, dass Goldman Sachs zur "Suche strategischer
Optionen" engagiert wurde.



Die Aktionäre von Chiron misstrauen dem Deal
und strafen die Aktie ab. Chiron notiert aktuell mit
einem Minus von 7,6 Prozent bei 44-15/16 US-Dollar. PathoGenesis
gewinnt 16 Prozent auf 38 US-Dollar.

[IWA Japan]

Gaps in PathoGenesis` product pipeline pushes it into Chiron deal.

By Dane Hamilton
Staff Reporter


Just being good isn`t enough.

That`s the lesson of PathoGenesis` (Nasdaq: PGNS - news) decision to sell itself to Chiron (Nasdaq: CHIR - news) for $700 million in cash. The new reality of the biotech industry is that even bringing a product to market, in itself a major feat in a high-risk industry, isn`t enough to ensure independence for smaller players.

That`s why observers expect to see a spate of deals like Monday`s Chiron-PathoGenesis agreement, which sent PathoGenesis shares up 16% and pushed Chiron down 5.6%. With big drug companies combining and investors ratcheting up expectations for big and small outfits alike, even a successful company like PathoGenesis found that having a partner makes more sense than going it alone.

Possible candidates for mergers-and-acquisition activity include Coulter (Nasdaq: CLTR - news) , Antigenics (Nasdaq: AGEN - news) and Cell Pathways (Nasdaq: CLPA - news) , analysts say. All these companies have lead products in late-stage development, but fewer products in the pipeline. Coulter and Cell Pathways couldn`t be reached for immediate comment, but Antigenics "is not averse" to adding to its pipeline, says spokesman Gary Foster, noting that the company just raised $105 million in a recent IPO.

Milestone
The proposed sale comes despite PathoGenesis having achieved a key biotech-industry milestone: It brought a drug through the myriad pitfalls of the years-long development process and is now selling it.

The drug is tobramycin, or TOBI, for cystic fibrosis and serious lung infections, which is generating $20.4 million in second-quarter sales, a 44% gain from a year earlier. The drug, approved in the U.S. and five other markets, was quickly bringing PathoGenesis closer to profitability.

But its other products are many years from the market, leaving a hole in its drug-development pipeline that it would either have to fill through acquisitions or through selling out to a much stronger company like Chiron. It chose the latter, hiring Goldman Sachs in June to explore "strategic options."

"Investors can`t wait another six years for the company to develop other products," said Tim Bepler, fund manager with the Orbitex Health & Bioscience fund, which doesn`t hold either Chiron or PathoGenesis. "It`s a trend that`s going to continue in this very fragmented industry."

R&D
New products are crucial to biotech company success, but many are also suffering from a lack of scientific staff, like chemists and biologists, another key reason for a rise in forecasted mergers and acquisitions. Chiron`s purchase adds nearly 300 PathoGenesis employees to its payrolls, of which the least likely to go will be the research and development staff, analysts say.

"Chemists are in very short supply now, and the need for product and scientists is driving this whole thing," says Stefan D. Loren, analyst with Legg Mason Wood Walker , referring to deals such as Millennium Pharmaceuticals` (Nasdaq: MLNM - news) recent purchase of Cambridge Discovery for about $52 million.

Eric Roberts, Lehman Brothers` managing director for health care corporate finance, says mergers and acquisitions have become crucial to maintaining high biotech stock valuations. He said that while previously companies were rated on a multiple of 15-to-16 times projected revenue two years out, now they are rated on 40-to-50 times revenue.

"Our phone has been ringing off the hook with people wanting to do M&A deals," says Roberts.

Atypical
Analysts say Chiron`s purchase of PathoGenesis brings it a new kind of product to add to its stable of vaccines and pharmaceuticals on the market and rich product pipeline, reflected in Chiron`s market capitalization of $8.2 billion, compared with PathoGenesis` $629 million as of Friday.

And the likelihood that this deal will fall apart is small, if trading in PathoGenesis is any indication. Stock in the target company rose to 38 Monday, just below the Chiron offer of $38.50 a share.

That`s because Chiron`s $700 million offer is in cash and not shares, as is typical for biotech company acquisitions. A cash offer is less subject to share price volatility that may quash a deal, such as the pending purchase of Anesta (Nasdaq: NSTA - news) by Cephalon (Nasdaq: CEPH - news) . Just after Cephalon announced the Anesta all-stock purchase, Cephalon shares plunged on negative drug-development news, raising doubts about whether Anesta shareholders would approve the deal.

Chiron shares fell 2 23/32 to 45 29/32, reflecting the impact of the purchase on Chiron`s earnings. Chiron says the purchase, which was approved by boards of both companies, will dilute earnings this year and next, but likely be accretive to earnings after that.

Chiron says it will pay for PathoGenesis out of its cash pile of $1.5 billion, which was generated through the sale of products like Proleukin for kidney cancer, Betaseron for multiple sclerosis and Regranex for diabetic foot ulcers.

"We have substantial cash and have looked for ways to invest that money," says Sean Lance, chief executive of Chiron, which is about 44% owned by Novartis (NYSE: NVS - news) , the Swiss drug company. "We believe PathoGenesis has very excellent long-term potential."

See TheStreet.com`s full site for more of its unique insider`s perspective on Wall Street.


Email this story - View most popular stories emailed